– 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models – ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model – Initial ATNM-400 preclinical data to be…

AMSTERDAM, 27. März 2025 /PRNewswire/ — HFCL Limited (HFCL), ein weltweit führender Anbieter von Telekommunikationslösungen der nächsten Generation, stellte heute auf der FTTH Conference 2025 in Amsterdam seine bahnbrechende optische Faser Eka™. Die gemeinsam mit europäischen…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.